Literature DB >> 17238227

In search of a corrected prescription drug elasticity estimate: a meta-regression approach.

Marin C Gemmill1, Joan Costa-Font, Alistair McGuire.   

Abstract

An understanding of the relationship between cost sharing and drug consumption depends on consistent and unbiased price elasticity estimates. However, there is wide heterogeneity among studies, which constrains the applicability of elasticity estimates for empirical purposes and policy simulation. This paper attempts to provide a corrected measure of the drug price elasticity by employing meta-regression analysis (MRA). The results indicate that the elasticity estimates are significantly different from zero, and the corrected elasticity is -0.209 when the results are made robust to heteroskedasticity and clustering of observations. Elasticity values are higher when the study was published in an economic journal, when the study employed a greater number of observations, and when the study used aggregate data. Elasticity estimates are lower when the institutional setting was a tax-based health insurance system.

Mesh:

Year:  2007        PMID: 17238227     DOI: 10.1002/hec.1190

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  9 in total

1.  The impact of repeated cost containment policies on pharmaceutical expenditure: experience in Spain.

Authors:  Iván Moreno-Torres; Jaume Puig-Junoy; Josep M Raya
Journal:  Eur J Health Econ       Date:  2010-09-01

2.  Impact of pharmacy benefit design on prescription drug utilization: a fixed effects analysis of plan sponsor data.

Authors:  M Christopher Roebuck; Joshua N Liberman
Journal:  Health Serv Res       Date:  2009-01-28       Impact factor: 3.402

3.  Effect of an expenditure cap on low-income seniors' drug use and spending in a state pharmacy assistance program.

Authors:  Christine E Bishop; Andrew M Ryan; Daniel M Gilden; Joanna Kubisiak; Cindy Parks Thomas
Journal:  Health Serv Res       Date:  2009-03-02       Impact factor: 3.402

Review 4.  A systematic umbrella review of the association of prescription drug insurance and cost-sharing with drug use, health services use, and health.

Authors:  G Emmanuel Guindon; Tooba Fatima; Sophiya Garasia; Kimia Khoee
Journal:  BMC Health Serv Res       Date:  2022-03-03       Impact factor: 2.655

5.  Pharmaceutical regulation in Europe and its impact on corporate R&D.

Authors:  Stephan Eger; Jörg C Mahlich
Journal:  Health Econ Rev       Date:  2014-10-03

6.  A comparison of generic drug prices in seven European countries: a methodological analysis.

Authors:  Olivier J Wouters; Panos G Kanavos
Journal:  BMC Health Serv Res       Date:  2017-03-31       Impact factor: 2.655

7.  Co-insurance and health care utilization in Japanese patients with rheumatoid arthritis: a discontinuity regression approach.

Authors:  Jörg Mahlich; Rosarin Sruamsiri
Journal:  Int J Equity Health       Date:  2019-01-28

8.  The effect of pharmaceutical co-payment increase on the use of social assistance-A natural experiment study.

Authors:  Hanna Rättö; Katri Aaltonen
Journal:  PLoS One       Date:  2021-05-05       Impact factor: 3.240

9.  Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending.

Authors:  Olivier J Wouters; Panos G Kanavos; Martin McKEE
Journal:  Milbank Q       Date:  2017-09       Impact factor: 4.911

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.